18 Jan Quell Therapeutics
Luke Henry, Ph.D., Chief Business Officer
April 21 | 11:45am | Gaudi 2 Ballroom
London, United Kingdom
Quell Therapeutics is developing engineered T-regulatory cell therapies that aim to harness, direct, and optimize their immune suppressive properties to address serious immune conditions. The company is leveraging its pioneering phenotype lock technology, unique multi-modular platform, and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency, and stability than earlier generations of Treg cell therapy approaches. Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. The company is on track to begin its Phase I/II LIBERATE trial with QEL-001 in the first quarter of 2022 and recently expanded its GMP manufacturing capabilities to scale up production for clinical trials. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.